{
    "analytics_identifier":  null,
    "base_path":  "/guidance/fees-applied-to-animal-medicine-authorisation-applications",
    "content_id":  "a1547374-9dbe-426e-8b97-10d423ad9bdf",
    "description":  "Definitive fees charged for applications under Schedule 7 of the Veterinary Medicines Regulations 2013.",
    "details":  {
                    "attachments":  [

                                    ],
                    "body":  "\u003cdiv class=\"govspeak\"\u003e\u003cp\u003eDefinitive fees charged for applications are set out in \u003ca rel=\"external\" href=\"https://www.legislation.gov.uk/uksi/2013/2033/schedule/7\" class=\"govuk-link\"\u003eSchedule 7 of the Veterinary Medicines Regulations 2013\u003c/a\u003e and are reproduced here for reference.\u003c/p\u003e\n\n\u003cp\u003eThe fees listed below are Pounds Sterling (£).\u003c/p\u003e\n\n\u003ch2 id=\"parallel-submission-administrative-reductions\"\u003eParallel submission administrative reductions\u003c/h2\u003e\n\n\u003cp\u003eAs we operate on a cost recovery basis, fees are charged in order to cover the work undertaken by the VMD. In cases where parallel submissions are made, some fees for the parallel NI applications will be administratively reduced.\nThe reduced fees will take account of the additional administrative activities we will need to perform.\u003c/p\u003e\n\n\u003ch3 id=\"new-gb-ma-and-national-only-ni-ma\"\u003eNew GB MA and national only NI MA\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/01/2021\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI01\u003c/th\u003e\n      \u003ctd\u003eNew pharmaceutical or immunological parallel submission for identical national GB and NI MAs. Full fee in respect of the GB MA plus reduced fee per application\u003c/td\u003e\n      \u003ctd\u003e685\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"new-gb-ma-and-mutually-recognised-ma-with-ni-as-cms\"\u003eNew GB MA and mutually recognised MA with NI as CMS\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/01/2021\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI02\u003c/th\u003e\n      \u003ctd\u003eNew pharmaceutical or immunological parallel submission for identical GB MA and mutually recognised MA with NI as CMS. Full fee in respect of the GB MA plus reduced fee per application\u003c/td\u003e\n      \u003ctd\u003e1,504\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"variations-gb-ma-and-national-ni-ma\"\u003eVariations: GB MA and national NI MA\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eReduced fee for NI application from 01/01/2021\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI03\u003c/th\u003e\n      \u003ctd\u003eType IA [now referred to as a Variation Not Requiring Assessment (VNRA)]: parallel submission of identical Type I A changes to identical national GB MA and NI MAs. The full fee is charged for the application to the GB MA plus a reduced fee for the application to the NI MA\u003c/td\u003e\n      \u003ctd\u003e273\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI04\u003c/th\u003e\n      \u003ctd\u003eType IB [now referred to as a Variation Requiring Assessment (VRA) -reduced]: parallel submission of identical Type IB changes to identical national GB MA and NI MAs. The full fee is charged for the application to the GB MA plus reduced fee for the application to the NI MA.\u003c/td\u003e\n      \u003ctd\u003e273\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI05\u003c/th\u003e\n      \u003ctd\u003eType II [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]: parallel submission of identical Type II changes to identical national GB MA and NI MAs. The full fee is charged for the application to the GB MA plus reduced fee for the application to the NI MA.\u003c/td\u003e\n      \u003ctd\u003e273\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"variations-gb-ma-and-mutually-recognised-ni-ma\"\u003eVariations: GB MA and mutually recognised NI MA\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eReduced fee for NI applications from 01/01/2021\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eNI06\u003c/th\u003e\n      \u003ctd\u003eType II [now referred to as a Variation Requiring Assessment (VRA – standard / extended: parallel submission of identical Type II changes to identical national GB MA and mutually recognised NI MA. The full fee in respect of the application for the GB MA plus reduced fee for the application to the mutually recognised NI MA\u003c/td\u003e\n      \u003ctd\u003e531\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003cp\u003eThe full CMS fee in respect of VNRA and VRA – reduced, will apply to mutually recognised NI MAs.\u003c/p\u003e\n\n\u003ch2 id=\"maximum-residue-limits\"\u003eMaximum Residue Limits\u003c/h2\u003e\n\n\u003cp\u003eThe application fee to establish an MRL in GB that is set out in legislation is £62,300, based on the current EU fee. However, we will administratively reduce this to £15,000 and, in accordance with our cost recovery principles, we  will review this fee in 12 months in light of our experience.\u003c/p\u003e\n\n\u003cp\u003eThe fees for making amendments (including extensions) to currently approved MRLs, that are also set out in legislation, are £20,103 based on the current EU fee. However, we will administratively reduce this to £5,390 and, in accordance with our cost recovery principles, we will review these fees in 12 months in light of our experience.\u003c/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee Code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/01/21\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMRL01\u003c/th\u003e\n      \u003ctd\u003eNew MRL\u003c/td\u003e\n      \u003ctd\u003e15,000\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMRL02\u003c/th\u003e\n      \u003ctd\u003eMRL (extensions/amendments)\u003c/td\u003e\n      \u003ctd\u003e5,390\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"provision-of-advice\"\u003eProvision of advice\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee Code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eADV1\u003c/th\u003e\n      \u003ctd\u003eThe fee for an application for written advice from the Secretary of State as to whether a product requires a marketing authorisation\u003c/td\u003e\n      \u003ctd\u003e885\u003c/td\u003e\n      \u003ctd\u003e885\u003c/td\u003e\n      \u003ctd\u003e54\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"new-marketing-authorisation--pharmaceutical\"\u003eNew marketing authorisation -pharmaceutical\u003c/h2\u003e\n\n\u003ch3 id=\"full-national-pharmaceutical-applications\"\u003eFull national pharmaceutical applications\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1010\u003c/th\u003e\n      \u003ctd\u003eBase Fee\u003c/td\u003e\n      \u003ctd\u003e13,530\u003c/td\u003e\n      \u003ctd\u003e13,530\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e K101-080\u003c/th\u003e\n      \u003ctd\u003eFood-producing target species\u003c/td\u003e\n      \u003ctd\u003e3,905\u003c/td\u003e\n      \u003ctd\u003e3,905\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e K101-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e7,465\u003c/td\u003e\n      \u003ctd\u003e7,465\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e K101-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e6,525\u003c/td\u003e\n      \u003ctd\u003e6,525\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e6,465\u003c/td\u003e\n      \u003ctd\u003e6,465\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e4,310\u003c/td\u003e\n      \u003ctd\u003e4,310\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e K101-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,970\u003c/td\u003e\n      \u003ctd\u003e3,970\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,495\u003c/td\u003e\n      \u003ctd\u003e2,495\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,695\u003c/td\u003e\n      \u003ctd\u003e2,695\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,215\u003c/td\u003e\n      \u003ctd\u003e1,215\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK101-300\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"bibliographic-national-pharmaceutical-applications\"\u003eBibliographic national pharmaceutical applications\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1020\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e12,115\u003c/td\u003e\n      \u003ctd\u003e12,115\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-080\u003c/th\u003e\n      \u003ctd\u003eFood-producing target species\u003c/td\u003e\n      \u003ctd\u003e3,585\u003c/td\u003e\n      \u003ctd\u003e3,585\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e6,595\u003c/td\u003e\n      \u003ctd\u003e6,595\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e K102-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e5,855\u003c/td\u003e\n      \u003ctd\u003e5,855\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e6,125\u003c/td\u003e\n      \u003ctd\u003e6,125\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e4,105\u003c/td\u003e\n      \u003ctd\u003e4,105\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,565\u003c/td\u003e\n      \u003ctd\u003e3,565\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,090\u003c/td\u003e\n      \u003ctd\u003e2,090\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,490\u003c/td\u003e\n      \u003ctd\u003e2,490\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,010\u003c/td\u003e\n      \u003ctd\u003e1,010\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK102-300\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"pharmacologically-equivalent-product--national-mas---uk-authorised-reference-product\"\u003ePharmacologically-equivalent product – national MAs - UK authorised reference product\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1030\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e7,195\u003c/td\u003e\n      \u003ctd\u003e7,195\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-080\u003c/th\u003e\n      \u003ctd\u003eFood-producing target species\u003c/td\u003e\n      \u003ctd\u003e2,155\u003c/td\u003e\n      \u003ctd\u003e2,155\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e5,885\u003c/td\u003e\n      \u003ctd\u003e5,885\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e5,590\u003c/td\u003e\n      \u003ctd\u003e5,590\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e605\u003c/td\u003e\n      \u003ctd\u003e605\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e4,040\u003c/td\u003e\n      \u003ctd\u003e4,040\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,235\u003c/td\u003e\n      \u003ctd\u003e3,235\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,425\u003c/td\u003e\n      \u003ctd\u003e2,425\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,550\u003c/td\u003e\n      \u003ctd\u003e1,550\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,620\u003c/td\u003e\n      \u003ctd\u003e1,620\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e740\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK103-300\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"pharmacologicallyequivalent-product--mutually-recognised-mas--eu-authorised-reference-product-ni-only\"\u003ePharmacologically‐equivalent product – mutually recognised MAs ‐ EU authorised reference product (NI only):\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1040\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e9,220\u003c/td\u003e\n      \u003ctd\u003e9,220\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-080\u003c/th\u003e\n      \u003ctd\u003eFood-producing target species\u003c/td\u003e\n      \u003ctd\u003e2,760\u003c/td\u003e\n      \u003ctd\u003e2,760\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e7,495\u003c/td\u003e\n      \u003ctd\u003e7,495\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e7,155\u003c/td\u003e\n      \u003ctd\u003e7,155\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e775\u003c/td\u003e\n      \u003ctd\u003e775\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e5,165\u003c/td\u003e\n      \u003ctd\u003e5,165\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e4,135\u003c/td\u003e\n      \u003ctd\u003e4,135\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,100\u003c/td\u003e\n      \u003ctd\u003e3,100\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,980\u003c/td\u003e\n      \u003ctd\u003e1,980\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,070\u003c/td\u003e\n      \u003ctd\u003e2,070\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e945\u003c/td\u003e\n      \u003ctd\u003e945\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK104-300\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e3,705\u003c/td\u003e\n      \u003ctd\u003e3,705\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"decentralised-or-mutual-recognition-ni-cms\"\u003eDecentralised or Mutual Recognition (NI CMS)\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1050\u003c/th\u003e\n      \u003ctd\u003eBase Fee\u003c/td\u003e\n      \u003ctd\u003e6,515\u003c/td\u003e\n      \u003ctd\u003e6,515\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-080\u003c/th\u003e\n      \u003ctd\u003eFood-producing target species\u003c/td\u003e\n      \u003ctd\u003e1,415\u003c/td\u003e\n      \u003ctd\u003e1,415\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e2,630\u003c/td\u003e\n      \u003ctd\u003e2,630\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e2,295\u003c/td\u003e\n      \u003ctd\u003e2,295\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e330\u003c/td\u003e\n      \u003ctd\u003e330\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,085\u003c/td\u003e\n      \u003ctd\u003e2,085\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,475\u003c/td\u003e\n      \u003ctd\u003e1,475\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal (applies for a maximum of 2 additional species)\u003c/td\u003e\n      \u003ctd\u003e1,280\u003c/td\u003e\n      \u003ctd\u003e1,280\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal (applies for a maximum of 2 additional species)\u003c/td\u003e\n      \u003ctd\u003e805\u003c/td\u003e\n      \u003ctd\u003e805\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e940\u003c/td\u003e\n      \u003ctd\u003e940\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e405\u003c/td\u003e\n      \u003ctd\u003e405\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-300\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e1,685\u003c/td\u003e\n      \u003ctd\u003e1,685\u003c/td\u003e\n      \u003ctd\u003e7\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"new-marketing-authorisations---immunological-or-biosimilar\"\u003eNew marketing authorisations - immunological or biosimilar\u003c/h2\u003e\n\n\u003ch3 id=\"full-national-immunological-or-biosimilar-applications\"\u003eFull national immunological or biosimilar applications\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3010\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e11,775\u003c/td\u003e\n      \u003ctd\u003e11,775\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-110\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK and for each new combination of active ingredients\u003c/td\u003e\n      \u003ctd\u003e7,405\u003c/td\u003e\n      \u003ctd\u003e7,405\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-120\u003c/th\u003e\n      \u003ctd\u003eFor each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the UK and for each new combination of adjuvants or preservatives\u003c/td\u003e\n      \u003ctd\u003e1,345\u003c/td\u003e\n      \u003ctd\u003e1,345\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-140\u003c/th\u003e\n      \u003ctd\u003eFor each additional antigenic component\u003c/td\u003e\n      \u003ctd\u003e1,350\u003c/td\u003e\n      \u003ctd\u003e1,350\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-200\u003c/th\u003e\n      \u003ctd\u003eFor each additional species\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-230\u003c/th\u003e\n      \u003ctd\u003eFor each additional route of administration\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-304\u003c/th\u003e\n      \u003ctd\u003eSimultaneous application—fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK301-307\u003c/th\u003e\n      \u003ctd\u003eApplication for a marketing authorisation for an immunological product that is identical to a product already authorised in the UK but with a lesser number of antigens and that only contains antigens contained in that product\u003c/td\u003e\n      \u003ctd\u003e10,430\u003c/td\u003e\n      \u003ctd\u003e10,430\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"decentralised-or-mutual-recognition-ni-cms-1\"\u003eDecentralised or Mutual Recognition (NI CMS)\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3020\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e5,785\u003c/td\u003e\n      \u003ctd\u003e5,785\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-110\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK and for each new combination of active ingredients\u003c/td\u003e\n      \u003ctd\u003e2,490\u003c/td\u003e\n      \u003ctd\u003e2,490\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-120\u003c/th\u003e\n      \u003ctd\u003eFor each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the UK and for each new combination of adjuvants or preservatives\u003c/td\u003e\n      \u003ctd\u003e675\u003c/td\u003e\n      \u003ctd\u003e675\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-140\u003c/th\u003e\n      \u003ctd\u003eFor each additional antigenic component\u003c/td\u003e\n      \u003ctd\u003e405\u003c/td\u003e\n      \u003ctd\u003e405\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-200\u003c/th\u003e\n      \u003ctd\u003eFor each additional species (maximum of 2)\u003c/td\u003e\n      \u003ctd\u003e1,615\u003c/td\u003e\n      \u003ctd\u003e1,615\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-230\u003c/th\u003e\n      \u003ctd\u003eFor each additional route of administration\u003c/td\u003e\n      \u003ctd\u003e1,615\u003c/td\u003e\n      \u003ctd\u003e1,615\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-305\u003c/th\u003e\n      \u003ctd\u003eSimultaneous application—fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e1,685\u003c/td\u003e\n      \u003ctd\u003e1,685\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK302-308\u003c/th\u003e\n      \u003ctd\u003eApplication for a marketing authorisation for an immunological product that is identical to a product already authorised in the UK but with a lesser number of antigens and that only contains antigens contained in that product\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e5,380\u003c/td\u003e\n      \u003ctd\u003e9\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"exceptional-pharmaceutical-marketing-authorisation\"\u003eExceptional pharmaceutical marketing authorisation\u003c/h2\u003e\n\n\u003ch3 id=\"provisional-exceptional-pharmaceutical-marketing-authorisation\"\u003eProvisional exceptional pharmaceutical marketing authorisation\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1130\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e12,015\u003c/td\u003e\n      \u003ctd\u003e12,015\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-080\u003c/th\u003e\n      \u003ctd\u003eAdditional fee if any of the target species is a food-producing target species\u003c/td\u003e\n      \u003ctd\u003e3,905\u003c/td\u003e\n      \u003ctd\u003e3,905\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e5,850\u003c/td\u003e\n      \u003ctd\u003e5,850\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e4,910\u003c/td\u003e\n      \u003ctd\u003e4,910\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e710\u003c/td\u003e\n      \u003ctd\u003e710\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e5,955\u003c/td\u003e\n      \u003ctd\u003e5,955\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,800\u003c/td\u003e\n      \u003ctd\u003e3,800\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,965\u003c/td\u003e\n      \u003ctd\u003e2,965\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,485\u003c/td\u003e\n      \u003ctd\u003e1,485\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,185\u003c/td\u003e\n      \u003ctd\u003e2,185\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non food-producing animal\u003c/td\u003e\n      \u003ctd\u003e710\u003c/td\u003e\n      \u003ctd\u003e710\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK113-110\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3110\u003c/th\u003e\n      \u003ctd\u003eConversion of an exceptional marketing authorisation to full MA\u003c/td\u003e\n      \u003ctd\u003e3,000\u003c/td\u003e\n      \u003ctd\u003e5,865\u003c/td\u003e\n      \u003ctd\u003e14\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"limited-exceptional-pharmaceutical-marketing-authorisation\"\u003eLimited exceptional pharmaceutical marketing authorisation\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee Code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ1150\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e6,765\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-080\u003c/th\u003e\n      \u003ctd\u003eAdditional fee if any of the target species is a food-producing target species\u003c/td\u003e\n      \u003ctd\u003e1,952\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-090\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - food producing animal\u003c/td\u003e\n      \u003ctd\u003e3,732\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-100\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK - non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e3,262\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-150\u003c/th\u003e\n      \u003ctd\u003eFor each additional pack type\u003c/td\u003e\n      \u003ctd\u003e370\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-160\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e3,232\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-170\u003c/th\u003e\n      \u003ctd\u003eFor each additional active ingredient - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,155\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-180\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,985\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-190\u003c/th\u003e\n      \u003ctd\u003eFor each additional target species - non-food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,247\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-210\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - food-producing animal\u003c/td\u003e\n      \u003ctd\u003e1,347\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-220\u003c/th\u003e\n      \u003ctd\u003eFor each additional recommended route of administration - non food-producing animal\u003c/td\u003e\n      \u003ctd\u003e608\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK115-110\u003c/th\u003e\n      \u003ctd\u003eSimultaneous applications: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e1,447\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e12\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eConversion of an exceptional marketing authorisation to full MA\u003c/td\u003e\n      \u003ctd\u003e3,000\u003c/td\u003e\n      \u003ctd\u003e5,865\u003c/td\u003e\n      \u003ctd\u003e14\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"exceptional-immunological-authorisation\"\u003eExceptional immunological authorisation\u003c/h2\u003e\n\n\u003ch3 id=\"provisional-exceptional-immunological-authorisation\"\u003eProvisional exceptional Immunological authorisation\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee Code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3040\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e10,810\u003c/td\u003e\n      \u003ctd\u003e10,810\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-110\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK and for each new combination of active ingredients\u003c/td\u003e\n      \u003ctd\u003e5,650\u003c/td\u003e\n      \u003ctd\u003e5,650\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-120\u003c/th\u003e\n      \u003ctd\u003eFor each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the UK and for each new combination of adjuvants or preservatives\u003c/td\u003e\n      \u003ctd\u003e1,350\u003c/td\u003e\n      \u003ctd\u003e1,350\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-140\u003c/th\u003e\n      \u003ctd\u003eFor each additional antigenic component\u003c/td\u003e\n      \u003ctd\u003e1,190\u003c/td\u003e\n      \u003ctd\u003e1,190\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-200\u003c/th\u003e\n      \u003ctd\u003eFor each additional species\u003c/td\u003e\n      \u003ctd\u003e4,060\u003c/td\u003e\n      \u003ctd\u003e4,060\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-230\u003c/th\u003e\n      \u003ctd\u003eFor each additional route of administration\u003c/td\u003e\n      \u003ctd\u003e4,060\u003c/td\u003e\n      \u003ctd\u003e4,060\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK304-304\u003c/th\u003e\n      \u003ctd\u003eSimultaneous application—fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3110\u003c/th\u003e\n      \u003ctd\u003eConversion of an exceptional marketing authorisation to full MA\u003c/td\u003e\n      \u003ctd\u003e3,000\u003c/td\u003e\n      \u003ctd\u003e5,865\u003c/td\u003e\n      \u003ctd\u003e14\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"limited-exceptional-immunological-authorisation\"\u003eLimited exceptional Immunological authorisation\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3050\u003c/th\u003e\n      \u003ctd\u003eBase fee\u003c/td\u003e\n      \u003ctd\u003e5,887\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-110\u003c/th\u003e\n      \u003ctd\u003eFor each active ingredient not previously included in a veterinary medicinal product authorised in the UK and for each new combination of active ingredients\u003c/td\u003e\n      \u003ctd\u003e3,702\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-120\u003c/th\u003e\n      \u003ctd\u003eFor each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the UK and for each new combination of adjuvants or preservatives\u003c/td\u003e\n      \u003ctd\u003e672\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-140\u003c/th\u003e\n      \u003ctd\u003eFor each additional antigenic component\u003c/td\u003e\n      \u003ctd\u003e675\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-200\u003c/th\u003e\n      \u003ctd\u003eFor each additional species\u003c/td\u003e\n      \u003ctd\u003e2,690\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-230\u003c/th\u003e\n      \u003ctd\u003eFor each additional route of administration\u003c/td\u003e\n      \u003ctd\u003e2,690\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK305-304\u003c/th\u003e\n      \u003ctd\u003eSimultaneous application—fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e1,447\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e13\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eJ3110\u003c/th\u003e\n      \u003ctd\u003eConversion of an exceptional marketing authorisation to full MA\u003c/td\u003e\n      \u003ctd\u003e3,000\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e14\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"parallel-import\"\u003eParallel Import\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAP1\u003c/th\u003e\n      \u003ctd\u003eApplication where the imported product has not been authorised in accordance with the mutual recognition procedure or the decentralised procedure but where the imported product originates from the same manufacturing site as the product authorised in the UK\u003c/td\u003e\n      \u003ctd\u003e2,130\u003c/td\u003e\n      \u003ctd\u003e2,130\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAP2\u003c/th\u003e\n      \u003ctd\u003eWhere the imported product has been authorised in accordance with the mutual recognition procedure or decentralised procedure, and the NI is included in these procedures - import from 1 EU member State\u003c/td\u003e\n      \u003ctd\u003e1,755\u003c/td\u003e\n      \u003ctd\u003e1,755\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAP4\u003c/th\u003e\n      \u003ctd\u003eApplication to add an additional EU member State after the marketing authorisation has been granted—fee for each member State\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAP5\u003c/th\u003e\n      \u003ctd\u003eAny other application—fee for each EU member State from which the product is imported\u003c/td\u003e\n      \u003ctd\u003e4,710\u003c/td\u003e\n      \u003ctd\u003e4,710\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"animal-test-certificates\"\u003eAnimal Test Certificates\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eAL11\u003c/th\u003e\n      \u003ctd\u003eApplication - Type A (as set out in para 48(1)(a), (b) and (c))\u003c/td\u003e\n      \u003ctd\u003e345\u003c/td\u003e\n      \u003ctd\u003e345\u003c/td\u003e\n      \u003ctd\u003e48(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eAL12\u003c/th\u003e\n      \u003ctd\u003eApplication - Type S (as set out in para 48(2)\u003c/td\u003e\n      \u003ctd\u003e30\u003c/td\u003e\n      \u003ctd\u003e30\u003c/td\u003e\n      \u003ctd\u003e48(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eAL10\u003c/th\u003e\n      \u003ctd\u003eApplication - in any other case\u003c/td\u003e\n      \u003ctd\u003e815\u003c/td\u003e\n      \u003ctd\u003e815\u003c/td\u003e\n      \u003ctd\u003e48(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eAV10\u003c/th\u003e\n      \u003ctd\u003eVariation (for each change)\u003c/td\u003e\n      \u003ctd\u003e265\u003c/td\u003e\n      \u003ctd\u003e265\u003c/td\u003e\n      \u003ctd\u003e48(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eAR10\u003c/th\u003e\n      \u003ctd\u003eRenewal\u003c/td\u003e\n      \u003ctd\u003e130\u003c/td\u003e\n      \u003ctd\u003e130\u003c/td\u003e\n      \u003ctd\u003e48(5)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"variations-to-marketing-authorisations-mas-or-veterinary-homeopathic-remedies-vhrs\"\u003eVariations to Marketing Authorisations (MAs) or Veterinary Homeopathic Remedies (VHRs)\u003c/h2\u003e\n\n\u003cp\u003eFor ease of reference, we have included in the tables below new terminology to describe variations, which are now ‘variations not requiring assessment (VNRA)’ and ‘variations requiring assessment (VRA)’.\u003c/p\u003e\n\n\u003cp\u003eWe have updated the guidance \u003ca href=\"https://www.gov.uk/guidance/apply-to-change-a-marketing-authorisation-for-an-animal-medicine\" class=\"govuk-link\"\u003eVariations to a veterinary Marketing Authorisation or Homeopathic Remedy\u003c/a\u003e which explains these changes.\u003c/p\u003e\n\n\u003ch3 id=\"single-variation-applications\"\u003eSingle variation applications\u003c/h3\u003e\n\n\u003cp\u003eThe extension fee will continue to apply to these changes that are included in the list of Variations Requiring Assessment in published guidance.\u003c/p\u003e\n\n\u003cp\u003eSingle applications are for one change per MA. However, a single change being made to the terms of several MAs that don’t meet the definition of a ‘product range’ will be applied for as separate applications, can be considered a ‘grouped’ variation for fee purposes.\u003c/p\u003e\n\n\u003ch3 id=\"national\"\u003eNational\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-240\u003c/th\u003e\n      \u003ctd\u003eExtension - change of strength or potency or the addition of a new strength or potency\u003c/td\u003e\n      \u003ctd\u003e6,670\u003c/td\u003e\n      \u003ctd\u003e6,670\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-250\u003c/th\u003e\n      \u003ctd\u003eExtension - change of pharmaceutical form or the addition of a new pharmaceutical form\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-260\u003c/th\u003e\n      \u003ctd\u003eExtension - change of route of administration or the addition of a new one for an immunological product, or pharmaceutical product for a non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e5,390\u003c/td\u003e\n      \u003ctd\u003e5,390\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-270\u003c/th\u003e\n      \u003ctd\u003eExtension - change of route of administration or the addition of a new one for a pharmaceutical product for a food-producing animal\u003c/td\u003e\n      \u003ctd\u003e7,135\u003c/td\u003e\n      \u003ctd\u003e7,135\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-280\u003c/th\u003e\n      \u003ctd\u003eExtension - change or addition of food producing target species\u003c/td\u003e\n      \u003ctd\u003e9,620\u003c/td\u003e\n      \u003ctd\u003e9,620\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-300\u003c/th\u003e\n      \u003ctd\u003eExtension - change of active substance\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-310\u003c/th\u003e\n      \u003ctd\u003eExtension – change of bioavailability or change of pharmacokinetics\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e8,415\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK501-504\u003c/th\u003e\n      \u003ctd\u003eExtension - Simultaneous application: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTV11\u003c/th\u003e\n      \u003ctd\u003eType II  - now referred to as Variations Requiring Assessment (VRA) – standard / extended)\u003c/td\u003e\n      \u003ctd\u003e1,504\u003c/td\u003e\n      \u003ctd\u003e2,895\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTVB1\u003c/th\u003e\n      \u003ctd\u003eType IB - now referred to as Variations Requiring Assessment (VRA) – reduced\u003c/td\u003e\n      \u003ctd\u003e530\u003c/td\u003e\n      \u003ctd\u003e885\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTVA1\u003c/th\u003e\n      \u003ctd\u003eType IA - now referred to as Variations Not Requiring Assessment (VNRA)\u003c/td\u003e\n      \u003ctd\u003e400\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"mutually-recognised-ni-mas\"\u003eMutually recognised NI MAs:\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-240\u003c/th\u003e\n      \u003ctd\u003eExtension - change of strength or potency or the addition of a new strength or potency\u003c/td\u003e\n      \u003ctd\u003e1,998\u003c/td\u003e\n      \u003ctd\u003e1,998\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-250\u003c/th\u003e\n      \u003ctd\u003eExtension - change of pharmaceutical form or the addition of a new pharmaceutical form\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-260\u003c/th\u003e\n      \u003ctd\u003eExtension - change of route of administration or the addition of a new one for an immunological product, or pharmaceutical product for a non-food producing animal\u003c/td\u003e\n      \u003ctd\u003e1,737\u003c/td\u003e\n      \u003ctd\u003e1,737\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-270\u003c/th\u003e\n      \u003ctd\u003eExtension - change of route of administration or the addition of a new one for a pharmaceutical product for a food-producing animal\u003c/td\u003e\n      \u003ctd\u003e2,058\u003c/td\u003e\n      \u003ctd\u003e2,058\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-280\u003c/th\u003e\n      \u003ctd\u003eExtension - change or addition of food producing target species\u003c/td\u003e\n      \u003ctd\u003e2,547\u003c/td\u003e\n      \u003ctd\u003e2,547\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-300\u003c/th\u003e\n      \u003ctd\u003eExtension - change of active substance\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-310\u003c/th\u003e\n      \u003ctd\u003eExtension – change of bioavailability or change of pharmacokinetics\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e2,301\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK502-504\u003c/th\u003e\n      \u003ctd\u003eExtension - Simultaneous application: fee for each additional product in the application\u003c/td\u003e\n      \u003ctd\u003e1,011\u003c/td\u003e\n      \u003ctd\u003e1,011\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eECV1\u003c/th\u003e\n      \u003ctd\u003eType II  [now referred to as Variations Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e1,872\u003c/td\u003e\n      \u003ctd\u003e1,872\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eENB1\u003c/th\u003e\n      \u003ctd\u003eType IB [now referred to as Variations Requiring Assessment (VRA) - reduced]\u003c/td\u003e\n      \u003ctd\u003e531\u003c/td\u003e\n      \u003ctd\u003e531\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eENA1\u003c/th\u003e\n      \u003ctd\u003eType IA [now referred to as Variations Not Requiring Assessment (VNRA)]\u003c/td\u003e\n      \u003ctd\u003e273\u003c/td\u003e\n      \u003ctd\u003e273\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"grouped-variation-applications\"\u003eGrouped variation applications\u003c/h3\u003e\n\n\u003cp\u003eEach change per MA is counted as a ‘change’; therefore, if you are applying for 3 changes to 6 MAs these count as 18 changes for fee purposes.\u003c/p\u003e\n\n\u003cp\u003eThe fee for an extension-led application is the fee for that extension plus:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eif there is 1 variation in addition to the extension, the fee for that variation, or\u003c/li\u003e\n  \u003cli\u003eif there is more than 1 variation in addition to the extension, the fee that would be payable under a grouped variation of that type\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"national-1\"\u003eNational:\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTV11G\u003c/th\u003e\n      \u003ctd\u003eType II - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e2,181\u003c/td\u003e\n      \u003ctd\u003e6,280\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTV11X\u003c/th\u003e\n      \u003ctd\u003eType II - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e4,362\u003c/td\u003e\n      \u003ctd\u003e4,500\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTVB1G\u003c/th\u003e\n      \u003ctd\u003eType IB - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e708\u003c/td\u003e\n      \u003ctd\u003e1,770\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eTVB2G\u003c/th\u003e\n      \u003ctd\u003eType IB - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e1,416\u003c/td\u003e\n      \u003ctd\u003e4,500\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"mutually-recognised-ni-mas-1\"\u003eMutually recognised NI MAs:\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVC21\u003c/th\u003e\n      \u003ctd\u003eType II - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e3,768\u003c/td\u003e\n      \u003ctd\u003e3,768\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVC22\u003c/th\u003e\n      \u003ctd\u003eType II - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVCB1\u003c/th\u003e\n      \u003ctd\u003eType IB - for the first 9 changes[now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e1,062\u003c/td\u003e\n      \u003ctd\u003e1,062\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVCB2\u003c/th\u003e\n      \u003ctd\u003eType IB - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e17(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"workshare-variation-applications\"\u003eWorkshare variation applications\u003c/h3\u003e\n\n\u003cp\u003eEach change per MA is counted as a ‘change’; therefore, if you are applying for 3 changes to 6 MAs these count as 18 changes for fee purposes.\u003c/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVR29\u003c/th\u003e\n      \u003ctd\u003eInvolving nationally authorised products: Type II - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e6,030\u003c/td\u003e\n      \u003ctd\u003e18(3)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVR30\u003c/th\u003e\n      \u003ctd\u003eInvolving nationally authorised products: Type II - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e4,500\u003c/td\u003e\n      \u003ctd\u003e18(3)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVR31\u003c/th\u003e\n      \u003ctd\u003eInvolving nationally authorised products: Type IB - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e2,650\u003c/td\u003e\n      \u003ctd\u003e18(3)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVR32\u003c/th\u003e\n      \u003ctd\u003eInvolving nationally authorised products: Type IB - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e4,500\u003c/td\u003e\n      \u003ctd\u003e18(3)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVC23\u003c/th\u003e\n      \u003ctd\u003eInvolving mutually recognised products: Type II - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e3,372\u003c/td\u003e\n      \u003ctd\u003e18(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVCC2\u003c/th\u003e\n      \u003ctd\u003eInvolving mutually recognised products: Type II - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – standard / extended]\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e18(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVCB3\u003c/th\u003e\n      \u003ctd\u003eInvolving mutually recognised products: Type IB - for the first 9 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e954\u003c/td\u003e\n      \u003ctd\u003e18(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVR33\u003c/th\u003e\n      \u003ctd\u003eInvolving mutually recognised products: Type IB - for the 10th and each subsequent 10 changes [now referred to as a Variation Requiring Assessment (VRA) – reduced]\u003c/td\u003e\n      \u003ctd\u003e2,700\u003c/td\u003e\n      \u003ctd\u003e18(4)\u003c/td\u003e\n    \u003c/tr\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eEVRE1\u003c/th\u003e\n      \u003ctd\u003eFee per nationally authorised or mutually recognised MA included in a workshare application involving centrally authorised products\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e18(5)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"renewal-of-a-pharmaceutical-immunological-or-biosimilar-marketing-authorisation\"\u003eRenewal of a pharmaceutical, immunological or biosimilar marketing authorisation\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003ePR10\u003c/th\u003e\n      \u003ctd\u003eRenewal of MA\u003c/td\u003e\n      \u003ctd\u003e1,360\u003c/td\u003e\n      \u003ctd\u003e1,360\u003c/td\u003e\n      \u003ctd\u003e22(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003ePRP2\u003c/th\u003e\n      \u003ctd\u003eExceptional Marketing Authorisation - 1st reassessment\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e22(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003ePRP3\u003c/th\u003e\n      \u003ctd\u003eExceptional Marketing Authorisation - subsequent reassessment\u003c/td\u003e\n      \u003ctd\u003e1,360\u003c/td\u003e\n      \u003ctd\u003e1,360\u003c/td\u003e\n      \u003ctd\u003e22(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"mutual-recognition-and-decentralised-procedures\"\u003eMutual Recognition and Decentralised procedures\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eECM5\u003c/th\u003e\n      \u003ctd\u003eRenewal where NI is CMS\u003c/td\u003e\n      \u003ctd\u003e1,225\u003c/td\u003e\n      \u003ctd\u003e1,225\u003c/td\u003e\n      \u003ctd\u003e23(b)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"veterinary-homeopathic-remedy\"\u003eVeterinary homeopathic remedy\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA50\u003c/th\u003e\n      \u003ctd\u003eIf all stocks and the formulation have already been assessed - not more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e160\u003c/td\u003e\n      \u003ctd\u003e160\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA60\u003c/th\u003e\n      \u003ctd\u003eIf all stocks and the formulation have already been assessed - more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e375\u003c/td\u003e\n      \u003ctd\u003e375\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA30\u003c/th\u003e\n      \u003ctd\u003eIf either all the stocks have already been assessed but there is a new formulation or if the formulation has already been assessed but 1 or more stocks have not already been assessed - not more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA40\u003c/th\u003e\n      \u003ctd\u003eIf either all the stocks have already been assessed but there is a new formulation or if the formulation has already been assessed but 1 or more stocks have not already been assessed - more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e665\u003c/td\u003e\n      \u003ctd\u003e665\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA10\u003c/th\u003e\n      \u003ctd\u003eIf the formulation and at least 1 of the stocks has not already been assessed - not more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e760\u003c/td\u003e\n      \u003ctd\u003e760\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHA20\u003c/th\u003e\n      \u003ctd\u003eIf the formulation and at least 1 of the stocks has not already been assessed - more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e985\u003c/td\u003e\n      \u003ctd\u003e985\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHE10\u003c/th\u003e\n      \u003ctd\u003eIf the product is already authorised for human use in the UK or for human or veterinary use in the UK or in another member state - not more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e160\u003c/td\u003e\n      \u003ctd\u003e160\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHE20\u003c/th\u003e\n      \u003ctd\u003eIf the product is already authorised for human use in the UK or for human or veterinary use in the UK or in another member state - more than 5 stocks\u003c/td\u003e\n      \u003ctd\u003e375\u003c/td\u003e\n      \u003ctd\u003e375\u003c/td\u003e\n      \u003ctd\u003e24\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eHR10\u003c/th\u003e\n      \u003ctd\u003eRenewal of a homeopathic remedy\u003c/td\u003e\n      \u003ctd\u003e320\u003c/td\u003e\n      \u003ctd\u003e0\u003c/td\u003e\n      \u003ctd\u003e25\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"annual-fees-for-marketing-authorisations\"\u003eAnnual fees for marketing authorisations\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eYGAF1\u003c/th\u003e\n      \u003ctd\u003eGraded Annual Fee - % on turnover in the UK\u003c/td\u003e\n      \u003ctd\u003e0.67%\u003c/td\u003e\n      \u003ctd\u003e0.67%\u003c/td\u003e\n      \u003ctd\u003e26(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eYFAF1\u003c/th\u003e\n      \u003ctd\u003eFixed Annual Fee for each GB MA, NI MA and UK wide MA – turnover in the UK of authorised products equal to or greater than £230,000\u003c/td\u003e\n      \u003ctd\u003e230\u003c/td\u003e\n      \u003ctd\u003e230\u003c/td\u003e\n      \u003ctd\u003e26(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eYFAF2\u003c/th\u003e\n      \u003ctd\u003eFixed Annual Fee for each GB MA, NI MA and UK wide MA - turnover of authorised products less than £230,000\u003c/td\u003e\n      \u003ctd\u003e200\u003c/td\u003e\n      \u003ctd\u003e200\u003c/td\u003e\n      \u003ctd\u003e26(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e \u003c/td\u003e\n      \u003ctd\u003eFailure to provide an audit certificate: Base fee\u003c/td\u003e\n      \u003ctd\u003e11,300\u003c/td\u003e\n      \u003ctd\u003e11,300\u003c/td\u003e\n      \u003ctd\u003e27(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e \u003c/td\u003e\n      \u003ctd\u003eFailure to provide an audit certificate: Fee for each MA held\u003c/td\u003e\n      \u003ctd\u003e2,245\u003c/td\u003e\n      \u003ctd\u003e2,245\u003c/td\u003e\n      \u003ctd\u003e27(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"manufacturers-authorisation\"\u003eManufacturers authorisation\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMA60\u003c/th\u003e\n      \u003ctd\u003eApplication\u003c/td\u003e\n      \u003ctd\u003e3,040\u003c/td\u003e\n      \u003ctd\u003e3,040\u003c/td\u003e\n      \u003ctd\u003e28(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMA06\u003c/th\u003e\n      \u003ctd\u003eApplication - Schedule 6 products\u003c/td\u003e\n      \u003ctd\u003e530\u003c/td\u003e\n      \u003ctd\u003e530\u003c/td\u003e\n      \u003ctd\u003e28(b)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMV60\u003c/th\u003e\n      \u003ctd\u003eVariation requiring scientific or pharmaceutical assessment\u003c/td\u003e\n      \u003ctd\u003e636\u003c/td\u003e\n      \u003ctd\u003e545\u003c/td\u003e\n      \u003ctd\u003e29(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMV62\u003c/th\u003e\n      \u003ctd\u003eVariation - change of ownership\u003c/td\u003e\n      \u003ctd\u003e443\u003c/td\u003e\n      \u003ctd\u003e380\u003c/td\u003e\n      \u003ctd\u003e29(b)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMV13\u003c/th\u003e\n      \u003ctd\u003eVariation - Schedule 6 products\u003c/td\u003e\n      \u003ctd\u003e210\u003c/td\u003e\n      \u003ctd\u003e180\u003c/td\u003e\n      \u003ctd\u003e29(c)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMV70\u003c/th\u003e\n      \u003ctd\u003eVariation not requiring scientific or pharmaceutical assessment\u003c/td\u003e\n      \u003ctd\u003e350\u003c/td\u003e\n      \u003ctd\u003e300\u003c/td\u003e\n      \u003ctd\u003e29(d)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAU1\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - authorisation for each UK manufacturing site\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e30(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAU2\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - authorisation for each non-UK manufacturing site\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e30(1)b\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAS1\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - single batch\u003c/td\u003e\n      \u003ctd\u003e1,635\u003c/td\u003e\n      \u003ctd\u003e1,635\u003c/td\u003e\n      \u003ctd\u003e30(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAV1\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - variation requiring inspection - UK site\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e30(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAV3\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - variation requiring inspection - non-UK site\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e30(1)b\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMAV2\u003c/th\u003e\n      \u003ctd\u003eAutogenous vaccine - variation not requiring inspection\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e30(4)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eMF60\u003c/th\u003e\n      \u003ctd\u003eAnnual Fee - other than autogenous vaccines\u003c/td\u003e\n      \u003ctd\u003e550\u003c/td\u003e\n      \u003ctd\u003e495\u003c/td\u003e\n      \u003ctd\u003e31(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eYGAF3\u003c/th\u003e\n      \u003ctd\u003eAnnual Fee - autogenous vaccines - % of turnover in the UK in previous calendar year\u003c/td\u003e\n      \u003ctd\u003e0.67%\u003c/td\u003e\n      \u003ctd\u003e0.67%\u003c/td\u003e\n      \u003ctd\u003e31(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eAnnual fee - Schedule 6 products\u003c/td\u003e\n      \u003ctd\u003eno fee\u003c/td\u003e\n      \u003ctd\u003eno fee\u003c/td\u003e\n      \u003ctd\u003e31(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"specific-batch-control\"\u003eSpecific batch control\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBC10\u003c/th\u003e\n      \u003ctd\u003eAuthorisation to release a product under specific batch control\u003c/td\u003e\n      \u003ctd\u003e560\u003c/td\u003e\n      \u003ctd\u003e560\u003c/td\u003e\n      \u003ctd\u003e51 (a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBC15\u003c/th\u003e\n      \u003ctd\u003eAdditional batches at application where all subsequent batches affected by same issue - per additional batch\u003c/td\u003e\n      \u003ctd\u003e100\u003c/td\u003e\n      \u003ctd\u003e455\u003c/td\u003e\n      \u003ctd\u003e51(b)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBC81A\u003c/th\u003e\n      \u003ctd\u003eSubmission of results of tests carried out on a batch of immunological products prior to release on to the UK markets\u003c/td\u003e\n      \u003ctd\u003e80\u003c/td\u003e\n      \u003ctd\u003e80\u003c/td\u003e\n      \u003ctd\u003e52\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"manufacturing-site-inspections\"\u003eManufacturing site inspections\u003c/h2\u003e\n\n\u003cp\u003eIf a site is inspected for more than 1 type of authorisation at the same time, the inspection fee payable is the highest inspection fee plus 50% of any other applicable inspection fees.\u003c/p\u003e\n\n\u003cp\u003eFor non-UK sites only, travel and subsistence costs and, if applicable, translation costs are payable in addition to the inspection fee.\u003c/p\u003e\n\n\u003ch3 id=\"immunological-site-inspections---uk-sites\"\u003eImmunological site inspections - UK sites\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS40\u003c/th\u003e\n      \u003ctd\u003eSuper site\u003c/td\u003e\n      \u003ctd\u003e24,071\u003c/td\u003e\n      \u003ctd\u003e26,745\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS10\u003c/th\u003e\n      \u003ctd\u003eMajor site\u003c/td\u003e\n      \u003ctd\u003e16,785\u003c/td\u003e\n      \u003ctd\u003e18,650\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS20\u003c/th\u003e\n      \u003ctd\u003eStandard site\u003c/td\u003e\n      \u003ctd\u003e6,661\u003c/td\u003e\n      \u003ctd\u003e6,055\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS30\u003c/th\u003e\n      \u003ctd\u003eMinor site\u003c/td\u003e\n      \u003ctd\u003e4,757\u003c/td\u003e\n      \u003ctd\u003e5,285\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO33\u003c/th\u003e\n      \u003ctd\u003eAutogenous Vaccine Site Inspection\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e30(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"immunological-site-inspections--non-uk-sites\"\u003eImmunological site inspections – non-UK sites\u003c/h3\u003e\n\n\u003cp\u003eTravel \u0026amp; subsistence costs are payable in addition to these fees.\u003c/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS40A\u003c/th\u003e\n      \u003ctd\u003eSuper site\u003c/td\u003e\n      \u003ctd\u003e22,867\u003c/td\u003e\n      \u003ctd\u003e25,480\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS10A\u003c/th\u003e\n      \u003ctd\u003eMajor site\u003c/td\u003e\n      \u003ctd\u003e15,946\u003c/td\u003e\n      \u003ctd\u003e17,760\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS20A\u003c/th\u003e\n      \u003ctd\u003eStandard site\u003c/td\u003e\n      \u003ctd\u003e6,327\u003c/td\u003e\n      \u003ctd\u003e5,765\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS30A\u003c/th\u003e\n      \u003ctd\u003eMinor site\u003c/td\u003e\n      \u003ctd\u003e4,519\u003c/td\u003e\n      \u003ctd\u003e5,035\u003c/td\u003e\n      \u003ctd\u003e33\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO33A\u003c/th\u003e\n      \u003ctd\u003eAutogenous Vaccine Site Inspection\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e30(1)b\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"pharmaceutical-site-inspections---uk-sites\"\u003ePharmaceutical site inspections - UK sites\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS91\u003c/th\u003e\n      \u003ctd\u003eSuper site - Sterile\u003c/td\u003e\n      \u003ctd\u003e23,324\u003c/td\u003e\n      \u003ctd\u003e25,915\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS61\u003c/th\u003e\n      \u003ctd\u003eMajor site - Sterile\u003c/td\u003e\n      \u003ctd\u003e13,010\u003c/td\u003e\n      \u003ctd\u003e14,455\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS71\u003c/th\u003e\n      \u003ctd\u003eStandard site - Sterile\u003c/td\u003e\n      \u003ctd\u003e8,244\u003c/td\u003e\n      \u003ctd\u003e9,160\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS81\u003c/th\u003e\n      \u003ctd\u003eMinor site - Sterile\u003c/td\u003e\n      \u003ctd\u003e5,022\u003c/td\u003e\n      \u003ctd\u003e4,565\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO91\u003c/th\u003e\n      \u003ctd\u003eSuper site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e14,180\u003c/td\u003e\n      \u003ctd\u003e15,755\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO61\u003c/th\u003e\n      \u003ctd\u003eMajor site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e8,325\u003c/td\u003e\n      \u003ctd\u003e9,250\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO71\u003c/th\u003e\n      \u003ctd\u003eStandard site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e6,854\u003c/td\u003e\n      \u003ctd\u003e7,615\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO81\u003c/th\u003e\n      \u003ctd\u003eMinor site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e3,789\u003c/td\u003e\n      \u003ctd\u003e4,210\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA91\u003c/th\u003e\n      \u003ctd\u003eSuper site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e11,025\u003c/td\u003e\n      \u003ctd\u003e12,250\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA61\u003c/th\u003e\n      \u003ctd\u003eMajor site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e5,949\u003c/td\u003e\n      \u003ctd\u003e6,610\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA71\u003c/th\u003e\n      \u003ctd\u003eStandard site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e4,917\u003c/td\u003e\n      \u003ctd\u003e4,470\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA81\u003c/th\u003e\n      \u003ctd\u003eMinor site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e2,035\u003c/td\u003e\n      \u003ctd\u003e1,850\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO34\u003c/th\u003e\n      \u003ctd\u003eStandard site - Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e5,055\u003c/td\u003e\n      \u003ctd\u003e4,595\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO32\u003c/th\u003e\n      \u003ctd\u003eMinor site - Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e2,728\u003c/td\u003e\n      \u003ctd\u003e2,480\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"pharmaceutical-site-inspections--non-uk-sites\"\u003ePharmaceutical site inspections – non-UK sites\u003c/h3\u003e\n\n\u003cp\u003eTravel \u0026amp; subsistence costs are payable in addition to these fees.\u003c/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS91A\u003c/th\u003e\n      \u003ctd\u003eSuper site - Sterile\u003c/td\u003e\n      \u003ctd\u003e22,157\u003c/td\u003e\n      \u003ctd\u003e24,680\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS61A\u003c/th\u003e\n      \u003ctd\u003eMajor site - Sterile\u003c/td\u003e\n      \u003ctd\u003e12,359\u003c/td\u003e\n      \u003ctd\u003e13,770\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS71A\u003c/th\u003e\n      \u003ctd\u003eStandard site - Sterile\u003c/td\u003e\n      \u003ctd\u003e7,832\u003c/td\u003e\n      \u003ctd\u003e8,725\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS81A\u003c/th\u003e\n      \u003ctd\u003eMinor site - Sterile\u003c/td\u003e\n      \u003ctd\u003e4,770\u003c/td\u003e\n      \u003ctd\u003e4,350\u003c/td\u003e\n      \u003ctd\u003e34\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO91A\u003c/th\u003e\n      \u003ctd\u003eSuper site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e13,471\u003c/td\u003e\n      \u003ctd\u003e15,015\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO61A\u003c/th\u003e\n      \u003ctd\u003eMajor site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e7,909\u003c/td\u003e\n      \u003ctd\u003e8,810\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO71A\u003c/th\u003e\n      \u003ctd\u003eStandard site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e6,511\u003c/td\u003e\n      \u003ctd\u003e7,250\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-080\u003c/th\u003e\n      \u003ctd\u003eMinor site - non-sterile\u003c/td\u003e\n      \u003ctd\u003e3,600\u003c/td\u003e\n      \u003ctd\u003e4,010\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eK105-090\u003c/th\u003e\n      \u003ctd\u003eSuper site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e10,474\u003c/td\u003e\n      \u003ctd\u003e11,665\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA61A\u003c/th\u003e\n      \u003ctd\u003eMajor site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e5,652\u003c/td\u003e\n      \u003ctd\u003e6,295\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA71A\u003c/th\u003e\n      \u003ctd\u003eStandard site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e4,671\u003c/td\u003e\n      \u003ctd\u003e4,255\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSA81A\u003c/th\u003e\n      \u003ctd\u003eMinor site - Assembly of products only\u003c/td\u003e\n      \u003ctd\u003e1,933\u003c/td\u003e\n      \u003ctd\u003e1,760\u003c/td\u003e\n      \u003ctd\u003e36\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO34A\u003c/th\u003e\n      \u003ctd\u003eStandard site - Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e4,802\u003c/td\u003e\n      \u003ctd\u003e4,380\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSO32A\u003c/th\u003e\n      \u003ctd\u003eMinor site - Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e2,592\u003c/td\u003e\n      \u003ctd\u003e2,365\u003c/td\u003e\n      \u003ctd\u003e35\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"test-sites-blood-banks-stem-cells\"\u003eTest sites, Blood Banks, Stem Cells\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS47\u003c/th\u003e\n      \u003ctd\u003eTest site inspection - UK site\u003c/td\u003e\n      \u003ctd\u003e3,344\u003c/td\u003e\n      \u003ctd\u003e3,040\u003c/td\u003e\n      \u003ctd\u003e37\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSS47A\u003c/th\u003e\n      \u003ctd\u003eTest site inspection - non-UK site\u003c/td\u003e\n      \u003ctd\u003e3,177\u003c/td\u003e\n      \u003ctd\u003e2,900\u003c/td\u003e\n      \u003ctd\u003e37\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBBA1\u003c/th\u003e\n      \u003ctd\u003eBlood bank - authorisation to operate - first inspection\u003c/td\u003e\n      \u003ctd\u003e3,113\u003c/td\u003e\n      \u003ctd\u003e2,830\u003c/td\u003e\n      \u003ctd\u003e38(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBBA5\u003c/th\u003e\n      \u003ctd\u003eBlood bank - subsequent inspection - UK site\u003c/td\u003e\n      \u003ctd\u003e3,113\u003c/td\u003e\n      \u003ctd\u003e2,970\u003c/td\u003e\n      \u003ctd\u003e38(1)b(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBBA5A\u003c/th\u003e\n      \u003ctd\u003eBlood bank - subsequent inspection - non-UK site\u003c/td\u003e\n      \u003ctd\u003e2,966\u003c/td\u003e\n      \u003ctd\u003e2,830\u003c/td\u003e\n      \u003ctd\u003e38(1)b(ii)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eVariation of a blood bank authorisation\u003c/td\u003e\n      \u003ctd\u003e320\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e38(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBSC1\u003c/th\u003e\n      \u003ctd\u003eStem Cell product - authorisation\u003c/td\u003e\n      \u003ctd\u003e3,427\u003c/td\u003e\n      \u003ctd\u003e3,270\u003c/td\u003e\n      \u003ctd\u003e38(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBSC2\u003c/th\u003e\n      \u003ctd\u003eStem Cell product - subsequent inspection - UK site\u003c/td\u003e\n      \u003ctd\u003e3,092\u003c/td\u003e\n      \u003ctd\u003e3,435\u003c/td\u003e\n      \u003ctd\u003e38(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eBSV1\u003c/th\u003e\n      \u003ctd\u003eStem Cell product - variation\u003c/td\u003e\n      \u003ctd\u003e320\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e38(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"wholesale-dealers-authorisation\"\u003eWholesale Dealer’s authorisation\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWA30\u003c/th\u003e\n      \u003ctd\u003eApplication – turnover in the UK is more than or equal to £35,000\u003c/td\u003e\n      \u003ctd\u003e1,745\u003c/td\u003e\n      \u003ctd\u003e1,760\u003c/td\u003e\n      \u003ctd\u003e39(1)(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWA40\u003c/th\u003e\n      \u003ctd\u003eApplication - turnover in the UK is less than £35,000 or AVM-GSL, homeopathic or Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e785\u003c/td\u003e\n      \u003ctd\u003e785\u003c/td\u003e\n      \u003ctd\u003e39(1)(b)/(c)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWV30\u003c/th\u003e\n      \u003ctd\u003eVariation requiring scientific or pharmaceutical assessment\u003c/td\u003e\n      \u003ctd\u003e515\u003c/td\u003e\n      \u003ctd\u003e515\u003c/td\u003e\n      \u003ctd\u003e40(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWV31\u003c/th\u003e\n      \u003ctd\u003eVariation only involving change of ownership\u003c/td\u003e\n      \u003ctd\u003e430\u003c/td\u003e\n      \u003ctd\u003e430\u003c/td\u003e\n      \u003ctd\u003e40(b)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWV32\u003c/th\u003e\n      \u003ctd\u003eVariation not requiring scientific or pharmaceutical assessment\u003c/td\u003e\n      \u003ctd\u003e300\u003c/td\u003e\n      \u003ctd\u003e300\u003c/td\u003e\n      \u003ctd\u003e40(c)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWF30\u003c/th\u003e\n      \u003ctd\u003eAnnual Fee – turnover in the UK is more than or equal to £35,000\u003c/td\u003e\n      \u003ctd\u003e483\u003c/td\u003e\n      \u003ctd\u003e330\u003c/td\u003e\n      \u003ctd\u003e41(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWF31\u003c/th\u003e\n      \u003ctd\u003eAnnual Fee - turnover in the UK is less than £35,000 or AVM-GSL, or homeopathic remedies\u003c/td\u003e\n      \u003ctd\u003e315\u003c/td\u003e\n      \u003ctd\u003e215\u003c/td\u003e\n      \u003ctd\u003e41(1)b\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWF32\u003c/th\u003e\n      \u003ctd\u003eAnnual Fee -Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e215\u003c/td\u003e\n      \u003ctd\u003e215\u003c/td\u003e\n      \u003ctd\u003e41(1)c\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWIL10\u003c/th\u003e\n      \u003ctd\u003eInspection - AVM-GSL, homeopathic remedies\u003c/td\u003e\n      \u003ctd\u003e1,442\u003c/td\u003e\n      \u003ctd\u003e830\u003c/td\u003e\n      \u003ctd\u003e42(b)(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWIL10\u003c/th\u003e\n      \u003ctd\u003eInspection - turnover in the UK in previous calendar year is less than £35,000\u003c/td\u003e\n      \u003ctd\u003e1,442\u003c/td\u003e\n      \u003ctd\u003e830\u003c/td\u003e\n      \u003ctd\u003e42(b)(ii)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWIJ10\u003c/th\u003e\n      \u003ctd\u003eInspection - Schedule 6 products only\u003c/td\u003e\n      \u003ctd\u003e830\u003c/td\u003e\n      \u003ctd\u003e830\u003c/td\u003e\n      \u003ctd\u003e42(c)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWI01\u003c/th\u003e\n      \u003ctd\u003eInspection - Otherwise\u003c/td\u003e\n      \u003ctd\u003e3,058\u003c/td\u003e\n      \u003ctd\u003e1,760\u003c/td\u003e\n      \u003ctd\u003e42(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWDIC1\u003c/th\u003e\n      \u003ctd\u003eWholesale Dealers Import Certificate*\u003c/td\u003e\n      \u003ctd\u003e1,320\u003c/td\u003e\n      \u003ctd\u003e760\u003c/td\u003e\n      \u003ctd\u003e50(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003cp\u003e*only payable if, in the twelve-month period immediately before the application, the applicant has supplied the veterinary medicinal product to which the certificate relates in accordance with at least 100 certificates.\u003c/p\u003e\n\n\u003ch2 id=\"feedingstuffs\"\u003eFeedingstuffs\u003c/h2\u003e\n\n\u003cp\u003eWhere more than 1 of the activities below is carried out at 1 premises, only 1 fee (the highest) is payable.\u003c/p\u003e\n\n\u003cp\u003eNo fee is payable under sub-paragraph (1) in respect of an establishment where specified feed additives are manufactured if a veterinary medicinal product intended to be incorporated into feedingstuffs is manufactured at that establishment in accordance with a manufacturing authorisation.\u003c/p\u003e\n\n\u003ch3 id=\"great-britain\"\u003eGreat Britain\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA1\u003c/th\u003e\n      \u003ctd\u003eCategory 1 - Application for the approval of establishment manufacturing a specified feed additive\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e975\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR1\u003c/th\u003e\n      \u003ctd\u003eCategory 1 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e975\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN1\u003c/th\u003e\n      \u003ctd\u003eCategory 1 - Inspection\u003c/td\u003e\n      \u003ctd\u003e1,810\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA2\u003c/th\u003e\n      \u003ctd\u003eCategory 2 - Application for the approval of an establishment to manufacture a premixture\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e615\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR2\u003c/th\u003e\n      \u003ctd\u003eCategory 2 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e615\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN2\u003c/th\u003e\n      \u003ctd\u003eCategory 2 - Inspection\u003c/td\u003e\n      \u003ctd\u003e1,090\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA3\u003c/th\u003e\n      \u003ctd\u003eCategory 3 - Application for the approval of an establishment to manufacture feedingstuffs, using specified feed additives or veterinary medicinal products directly at any concentration, or using premixtures or specified feed additive complementary feedingstuffs\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e615\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR3\u003c/th\u003e\n      \u003ctd\u003eCategory 3 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e615\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN3\u003c/th\u003e\n      \u003ctd\u003eCategory 3 - Inspection\u003c/td\u003e\n      \u003ctd\u003e1,090\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA4\u003c/th\u003e\n      \u003ctd\u003eCategory 4 - Application for the approval of an establishment to manufacture feedingstuffs for placing on the market using a veterinary medicinal product or premixture where the concentration of veterinary medicinal product in the feedingstuffs is 2kg per tonne or more\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e415\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR4\u003c/th\u003e\n      \u003ctd\u003eCategory 4 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e415\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN4\u003c/th\u003e\n      \u003ctd\u003eCategory 4 - Inspection\u003c/td\u003e\n      \u003ctd\u003e961\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA5\u003c/th\u003e\n      \u003ctd\u003eCategory 5 - Application for the approval of an establishment to manufacture feedingstuffs using premixtures or specified feed additive complementary feedingstuffs containing specified feed additives when the feedingstuffs are to be placed on the market\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e205\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR5\u003c/th\u003e\n      \u003ctd\u003eCategory 5 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e205\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN5\u003c/th\u003e\n      \u003ctd\u003eCategory 5 - Inspection\u003c/td\u003e\n      \u003ctd\u003e405\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA6\u003c/th\u003e\n      \u003ctd\u003eCategory 6 - Application for the approval of an establishment to manufacture feedingstuffs for the manufacturer’s own use using a veterinary medicinal product or premixture where the concentration of veterinary medicinal product in the feedingstuffs is 2kg per tonne or more\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e150\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR6\u003c/th\u003e\n      \u003ctd\u003eCategory 6 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e150\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN6\u003c/th\u003e\n      \u003ctd\u003eCategory 6 - Inspection\u003c/td\u003e\n      \u003ctd\u003e320\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA7\u003c/th\u003e\n      \u003ctd\u003eCategory 7 - Application for the approval of an establishment to manufacture feedingstuffs using premixtures containing specified feed additives when the feedingstuffs are to be used by the person manufacturing the feedingstuffs\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e130\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR7\u003c/th\u003e\n      \u003ctd\u003eCategory 7 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e130\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN7\u003c/th\u003e\n      \u003ctd\u003eCategory 7 - Inspection\u003c/td\u003e\n      \u003ctd\u003e240\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDA8\u003c/th\u003e\n      \u003ctd\u003eCategory 8 - Application for approval as a distributor of specified feed additives, premixtures or feedingstuffs containing specified feed additives, or premixtures or feedingstuffs containing veterinary medicinal products\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e43(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDR8\u003c/th\u003e\n      \u003ctd\u003eCategory 8 - Renewal - Annual Fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e43(2)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eFDN8\u003c/th\u003e\n      \u003ctd\u003eCategory 8 - Inspection\u003c/td\u003e\n      \u003ctd\u003e227\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e44\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"northern-ireland\"\u003eNorthern Ireland\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 1 - Application for the approval of an establishment to manufacture a specified feed additive and the subsequent annual fee (no fee is payable for premises that already have a manufacturing authorisation relating to veterinary medicinal products for incorporating into feedingstuffs)\u003c/td\u003e\n      \u003ctd\u003e545\u003c/td\u003e\n      \u003ctd\u003e520\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 2 - Application for the approval of an establishment to manufacture a premixture and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e435\u003c/td\u003e\n      \u003ctd\u003e415\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 3 - Application for the approval of an establishment to manufacture feedingstuffs, using specified feed additives or veterinary medicinal products directly at any concentration, or using premixtures, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e435\u003c/td\u003e\n      \u003ctd\u003e415\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 4 - Application for the approval of an establishment to manufacture feedingstuffs for placing on the market using a veterinary medicinal product or premixture where the concentration of veterinary medicinal product in the feedingstuffs in 2kg per tonne or more, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e320\u003c/td\u003e\n      \u003ctd\u003e305\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 5 - Application for the approval of an establishment to manufacture feedingstuffs using premixtures containing specified feed additives when the feedingstuffs are to be placed on the market, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e170\u003c/td\u003e\n      \u003ctd\u003e160\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 6 - Application for the approval of an establishment to manufacture feedingstuffs for the manufacturer’s own use using a veterinary medicinal product or premixture where the concentration of veterinary medicinal product in the feedingstuffs is 2kg per tonne or more, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e131\u003c/td\u003e\n      \u003ctd\u003e125\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 7 - Application for the approval of an establishment to manufacture feedingstuffs using premixtures from specified feed additives when the feedingstuffs are to be used by the person manufacturing the feedingstuffs, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e110\u003c/td\u003e\n      \u003ctd\u003e105\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eCategory 8 - Application for approval as a distributor of specified feed additives, premixtures or feedingstuffs containing specified feed additives, or premixtures or feedingstuffs containing veterinary medicinal products, and the subsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e65\u003c/td\u003e\n      \u003ctd\u003e45(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"testing-of-samples\"\u003eTesting of samples\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eThe fee for testing a sample required to be submitted by the Secretary of State is the full economic cost of the test\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e47\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch3 id=\"inspection-improvement-notices\"\u003eInspection improvement notices\u003c/h3\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eThe full economic cost of any inspection necessary as a result of the issue of an improvement notice is payable by the person on whom the notice was served\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e59\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"approval-of-premises-for-supply-by-suitably-qualified-persons\"\u003eApproval of premises for supply by Suitably Qualified Persons\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e1601\u003c/th\u003e\n      \u003ctd\u003eApproval of premises\u003c/td\u003e\n      \u003ctd\u003e265\u003c/td\u003e\n      \u003ctd\u003e265\u003c/td\u003e\n      \u003ctd\u003e46(1)(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSQPAM\u003c/th\u003e\n      \u003ctd\u003eSubsequent annual fee\u003c/td\u003e\n      \u003ctd\u003e185\u003c/td\u003e\n      \u003ctd\u003e185\u003c/td\u003e\n      \u003ctd\u003e46(2)(a)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e1607\u003c/th\u003e\n      \u003ctd\u003eApproval of premises - horses only\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e46(1)(b)(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSQPAJ\u003c/th\u003e\n      \u003ctd\u003eSubsequent annual fee - horses only\u003c/td\u003e\n      \u003ctd\u003e95\u003c/td\u003e\n      \u003ctd\u003e95\u003c/td\u003e\n      \u003ctd\u003e46(2)(b)(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e1604\u003c/th\u003e\n      \u003ctd\u003eApproval of premises - horses and companion animals only\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e145\u003c/td\u003e\n      \u003ctd\u003e46(1)(b)(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSQPAS\u003c/th\u003e\n      \u003ctd\u003eSubsequent annual fee - horses and companion animals only\u003c/td\u003e\n      \u003ctd\u003e95\u003c/td\u003e\n      \u003ctd\u003e95\u003c/td\u003e\n      \u003ctd\u003e46(2)(b)(i)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003e1610\u003c/th\u003e\n      \u003ctd\u003eApproval of premises - companion animals only\u003c/td\u003e\n      \u003ctd\u003e110\u003c/td\u003e\n      \u003ctd\u003e110\u003c/td\u003e\n      \u003ctd\u003e46(1)(b)(ii)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSQPAC\u003c/th\u003e\n      \u003ctd\u003eSubsequent annual fee - companion animals only\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e70\u003c/td\u003e\n      \u003ctd\u003e46(2)(b)(ii)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"veterinary-surgeons-practice-inspection\"\u003eVeterinary surgeon’s practice inspection\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003ePI01\u003c/th\u003e\n      \u003ctd\u003eInspection\u003c/td\u003e\n      \u003ctd\u003e350\u003c/td\u003e\n      \u003ctd\u003e250\u003c/td\u003e\n      \u003ctd\u003e57(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"special-import-and-export-certificates\"\u003eSpecial Import and Export certificates\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eSIC1\u003c/th\u003e\n      \u003ctd\u003eSpecial Import Certificate (SIC) - postal application - product authorised in another country\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n      \u003ctd\u003e49(1)a\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eSpecial Import Certificate (SIC) - online application\u003c/td\u003e\n      \u003ctd\u003eno fee\u003c/td\u003e\n      \u003ctd\u003eno fee\u003c/td\u003e\n      \u003ctd\u003e49(3)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eWDIC1\u003c/th\u003e\n      \u003ctd\u003eWholesale Dealers Import Certificate*\u003c/td\u003e\n      \u003ctd\u003e1,320\u003c/td\u003e\n      \u003ctd\u003e760\u003c/td\u003e\n      \u003ctd\u003e50(1)\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eXPC1\u003c/th\u003e\n      \u003ctd\u003eExport Certificate (each)\u003c/td\u003e\n      \u003ctd\u003e30\u003c/td\u003e\n      \u003ctd\u003e30\u003c/td\u003e\n      \u003ctd\u003e53\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eXPC2\u003c/th\u003e\n      \u003ctd\u003eExport Certificate certified copy of each original\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n      \u003ctd\u003e15\u003c/td\u003e\n      \u003ctd\u003e53\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003cp\u003e*only payable if, in the twelve-month period immediately before the application, the applicant has supplied the veterinary medicinal product to which the certificate relates in accordance with at least 100 certificates.\u003c/p\u003e\n\n\u003ch2 id=\"appeal-to-the-veterinary-products-committee\"\u003eAppeal to the Veterinary Products Committee\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eVA30\u003c/th\u003e\n      \u003ctd\u003eThe fee for an appeal to the Veterinary Products Committee\u003c/td\u003e\n      \u003ctd\u003e1,500\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e55\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"referral-to-an-appointed-person\"\u003eReferral to an appointed person\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eThe appellant is liable for the full economic cost of a referral, subject to a maximum of £5,000. These fees are refunded if the decision is reversed\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e-\u003c/td\u003e\n      \u003ctd\u003e56\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003ch2 id=\"non-payment-of-fees\"\u003eNon-payment of fees\u003c/h2\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"col\"\u003eFee code\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eDescription\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/13\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eFee from 01/10/11\u003c/th\u003e\n      \u003cth scope=\"col\"\u003eVMR 2013 SCH 7 Para\u003c/th\u003e\n    \u003c/tr\u003e\n  \u003c/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003cth scope=\"row\"\u003eN/A\u003c/th\u003e\n      \u003ctd\u003eWhere any fee (other than any fee relating to a manufacturing authorisation or wholesale dealer’s authorisation) is not paid, the Secretary of State may, after giving 1 month’s written warning, suspend the processing of any application from the person who has not paid the fee\u003c/td\u003e\n      \u003ctd\u003e \u003c/td\u003e\n      \u003ctd\u003e \u003c/td\u003e\n      \u003ctd\u003e60\u003c/td\u003e\n    \u003c/tr\u003e\n  \u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e",
                    "change_history":  [
                                           {
                                               "note":  "Fee Codes NI07 and  NI08 removed",
                                               "public_timestamp":  "2022-08-03T15:03:33.000+01:00"
                                           },
                                           {
                                               "note":  "Updated fees tables to reflect the removal of some European fees categories and revised authorisation variation descriptions.",
                                               "public_timestamp":  "2022-01-28T08:58:07.000+00:00"
                                           },
                                           {
                                               "note":  "New MRL fees codes added",
                                               "public_timestamp":  "2021-08-18T15:19:32.000+01:00"
                                           },
                                           {
                                               "note":  "Updated fees table: Parallel submission administrative reductions",
                                               "public_timestamp":  "2021-06-17T16:48:06.000+01:00"
                                           },
                                           {
                                               "note":  "First published.",
                                               "public_timestamp":  "2021-01-06T16:55:00.000+00:00"
                                           }
                                       ],
                    "emphasised_organisations":  [
                                                     "da332ae4-d021-4800-aa53-826058a46923"
                                                 ],
                    "first_public_at":  "2021-01-06T16:55:00.000+00:00",
                    "political":  false,
                    "related_mainstream_content":  [

                                                   ],
                    "tags":  {
                                 "browse_pages":  [

                                                  ],
                                 "topics":  [

                                            ]
                             }
                },
    "document_type":  "detailed_guide",
    "first_published_at":  "2021-01-06T16:55:00+00:00",
    "links":  {
                  "available_translations":  [
                                                 {
                                                     "api_path":  "/api/content/guidance/fees-applied-to-animal-medicine-authorisation-applications",
                                                     "api_url":  "https://www.gov.uk/api/content/guidance/fees-applied-to-animal-medicine-authorisation-applications",
                                                     "base_path":  "/guidance/fees-applied-to-animal-medicine-authorisation-applications",
                                                     "content_id":  "a1547374-9dbe-426e-8b97-10d423ad9bdf",
                                                     "document_type":  "detailed_guide",
                                                     "links":  {

                                                               },
                                                     "locale":  "en",
                                                     "public_updated_at":  "2022-08-03T14:03:33Z",
                                                     "schema_name":  "detailed_guide",
                                                     "title":  "Fees applied to animal medicine authorisation applications",
                                                     "web_url":  "https://www.gov.uk/guidance/fees-applied-to-animal-medicine-authorisation-applications",
                                                     "withdrawn":  true
                                                 }
                                             ],
                  "government":  [
                                     {
                                         "api_path":  "/api/content/government/2015-conservative-government",
                                         "api_url":  "https://www.gov.uk/api/content/government/2015-conservative-government",
                                         "base_path":  "/government/2015-conservative-government",
                                         "content_id":  "d4fbc1b9-d47d-4386-af04-ac909f868f92",
                                         "details":  {
                                                         "current":  false,
                                                         "ended_on":  "2016-07-13T00:00:00+00:00",
                                                         "started_on":  "2015-05-08T00:00:00+00:00"
                                                     },
                                         "document_type":  "government",
                                         "links":  {

                                                   },
                                         "locale":  "en",
                                         "title":  "2015 to 2016 Cameron Conservative government",
                                         "web_url":  "https://www.gov.uk/government/2015-conservative-government"
                                     }
                                 ],
                  "organisations":  [
                                        {
                                            "analytics_identifier":  "EA60",
                                            "api_path":  "/api/content/government/organisations/veterinary-medicines-directorate",
                                            "api_url":  "https://www.gov.uk/api/content/government/organisations/veterinary-medicines-directorate",
                                            "base_path":  "/government/organisations/veterinary-medicines-directorate",
                                            "content_id":  "da332ae4-d021-4800-aa53-826058a46923",
                                            "details":  {
                                                            "acronym":  "VMD",
                                                            "brand":  "department-for-environment-food-rural-affairs",
                                                            "default_news_image":  {
                                                                                       "high_resolution_url":  "https://assets.publishing.service.gov.uk/media/5da99cfaed915d42a3e439fb/s960_VMD2017e.jpg",
                                                                                       "url":  "https://assets.publishing.service.gov.uk/media/5da99cfae5274a5cb0df8343/s300_VMD2017e.jpg"
                                                                                   },
                                                            "logo":  {
                                                                         "crest":  "single-identity",
                                                                         "formatted_title":  "Veterinary \u003cbr/\u003eMedicines \u003cbr/\u003eDirectorate"
                                                                     },
                                                            "organisation_govuk_status":  {
                                                                                              "status":  "live",
                                                                                              "updated_at":  null,
                                                                                              "url":  null
                                                                                          }
                                                        },
                                            "document_type":  "organisation",
                                            "links":  {

                                                      },
                                            "locale":  "en",
                                            "schema_name":  "organisation",
                                            "title":  "Veterinary Medicines Directorate",
                                            "web_url":  "https://www.gov.uk/government/organisations/veterinary-medicines-directorate",
                                            "withdrawn":  false
                                        }
                                    ],
                  "original_primary_publishing_organisation":  [
                                                                   {
                                                                       "analytics_identifier":  "EA60",
                                                                       "api_path":  "/api/content/government/organisations/veterinary-medicines-directorate",
                                                                       "api_url":  "https://www.gov.uk/api/content/government/organisations/veterinary-medicines-directorate",
                                                                       "base_path":  "/government/organisations/veterinary-medicines-directorate",
                                                                       "content_id":  "da332ae4-d021-4800-aa53-826058a46923",
                                                                       "details":  {
                                                                                       "acronym":  "VMD",
                                                                                       "brand":  "department-for-environment-food-rural-affairs",
                                                                                       "default_news_image":  {
                                                                                                                  "high_resolution_url":  "https://assets.publishing.service.gov.uk/media/5da99cfaed915d42a3e439fb/s960_VMD2017e.jpg",
                                                                                                                  "url":  "https://assets.publishing.service.gov.uk/media/5da99cfae5274a5cb0df8343/s300_VMD2017e.jpg"
                                                                                                              },
                                                                                       "logo":  {
                                                                                                    "crest":  "single-identity",
                                                                                                    "formatted_title":  "Veterinary \u003cbr/\u003eMedicines \u003cbr/\u003eDirectorate"
                                                                                                },
                                                                                       "organisation_govuk_status":  {
                                                                                                                         "status":  "live",
                                                                                                                         "updated_at":  null,
                                                                                                                         "url":  null
                                                                                                                     }
                                                                                   },
                                                                       "document_type":  "organisation",
                                                                       "links":  {

                                                                                 },
                                                                       "locale":  "en",
                                                                       "schema_name":  "organisation",
                                                                       "title":  "Veterinary Medicines Directorate",
                                                                       "web_url":  "https://www.gov.uk/government/organisations/veterinary-medicines-directorate",
                                                                       "withdrawn":  false
                                                                   }
                                                               ],
                  "primary_publishing_organisation":  [
                                                          {
                                                              "analytics_identifier":  "EA60",
                                                              "api_path":  "/api/content/government/organisations/veterinary-medicines-directorate",
                                                              "api_url":  "https://www.gov.uk/api/content/government/organisations/veterinary-medicines-directorate",
                                                              "base_path":  "/government/organisations/veterinary-medicines-directorate",
                                                              "content_id":  "da332ae4-d021-4800-aa53-826058a46923",
                                                              "details":  {
                                                                              "acronym":  "VMD",
                                                                              "brand":  "department-for-environment-food-rural-affairs",
                                                                              "default_news_image":  {
                                                                                                         "high_resolution_url":  "https://assets.publishing.service.gov.uk/media/5da99cfaed915d42a3e439fb/s960_VMD2017e.jpg",
                                                                                                         "url":  "https://assets.publishing.service.gov.uk/media/5da99cfae5274a5cb0df8343/s300_VMD2017e.jpg"
                                                                                                     },
                                                                              "logo":  {
                                                                                           "crest":  "single-identity",
                                                                                           "formatted_title":  "Veterinary \u003cbr/\u003eMedicines \u003cbr/\u003eDirectorate"
                                                                                       },
                                                                              "organisation_govuk_status":  {
                                                                                                                "status":  "live",
                                                                                                                "updated_at":  null,
                                                                                                                "url":  null
                                                                                                            }
                                                                          },
                                                              "document_type":  "organisation",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "schema_name":  "organisation",
                                                              "title":  "Veterinary Medicines Directorate",
                                                              "web_url":  "https://www.gov.uk/government/organisations/veterinary-medicines-directorate",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "suggested_ordered_related_items":  [
                                                          {
                                                              "api_path":  "/api/content/guidance/apply-to-change-a-marketing-authorisation-for-an-animal-medicine",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/apply-to-change-a-marketing-authorisation-for-an-animal-medicine",
                                                              "base_path":  "/guidance/apply-to-change-a-marketing-authorisation-for-an-animal-medicine",
                                                              "content_id":  "602d77b7-7631-11e4-a3cb-005056011aef",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-12-18T15:47:51Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Apply to change a veterinary Marketing Authorisation or Homeopathic Remedy",
                                                              "web_url":  "https://www.gov.uk/guidance/apply-to-change-a-marketing-authorisation-for-an-animal-medicine",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/government/publications/fees-calculator-new-and-variation-applications-for-animal-medicines",
                                                              "api_url":  "https://www.gov.uk/api/content/government/publications/fees-calculator-new-and-variation-applications-for-animal-medicines",
                                                              "base_path":  "/government/publications/fees-calculator-new-and-variation-applications-for-animal-medicines",
                                                              "content_id":  "6031387e-7631-11e4-a3cb-005056011aef",
                                                              "document_type":  "guidance",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2025-01-03T13:07:57Z",
                                                              "schema_name":  "publication",
                                                              "title":  "Fees calculator: new and variation applications for animal medicines in Northern Ireland",
                                                              "web_url":  "https://www.gov.uk/government/publications/fees-calculator-new-and-variation-applications-for-animal-medicines",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/marketing-authorisations-for-veterinary-medicines",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/marketing-authorisations-for-veterinary-medicines",
                                                              "base_path":  "/guidance/marketing-authorisations-for-veterinary-medicines",
                                                              "content_id":  "db53b0eb-564b-4abc-b0dd-cb39ac1c2fd1",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-07-09T08:17:20Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Marketing authorisations for veterinary medicines",
                                                              "web_url":  "https://www.gov.uk/guidance/marketing-authorisations-for-veterinary-medicines",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/exemption-from-authorisation-for-medicines-for-small-pet-animals",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/exemption-from-authorisation-for-medicines-for-small-pet-animals",
                                                              "base_path":  "/guidance/exemption-from-authorisation-for-medicines-for-small-pet-animals",
                                                              "content_id":  "01756b53-8cad-4765-9a82-f0ee8ed999a7",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-12-18T12:34:07Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Exemption from authorisation for medicines for small pet animals",
                                                              "web_url":  "https://www.gov.uk/guidance/exemption-from-authorisation-for-medicines-for-small-pet-animals",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/apply-for-autogenous-vaccine-non-food-animal-blood-bank-equine-stem-cell-centre-authorisation",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/apply-for-autogenous-vaccine-non-food-animal-blood-bank-equine-stem-cell-centre-authorisation",
                                                              "base_path":  "/guidance/apply-for-autogenous-vaccine-non-food-animal-blood-bank-equine-stem-cell-centre-authorisation",
                                                              "content_id":  "ebd95612-5a72-40af-b53e-b62cfc33e64e",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-09-09T10:31:33Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Apply for Specific Manufacturing Authorisation",
                                                              "web_url":  "https://www.gov.uk/guidance/apply-for-autogenous-vaccine-non-food-animal-blood-bank-equine-stem-cell-centre-authorisation",
                                                              "withdrawn":  false
                                                          }
                                                      ]
              },
    "locale":  "en",
    "phase":  "live",
    "public_updated_at":  "2022-08-03T15:03:33+01:00",
    "publishing_app":  "whitehall",
    "publishing_request_id":  "23977-1659535412.975-10.13.2.89-2127",
    "publishing_scheduled_at":  null,
    "rendering_app":  "government-frontend",
    "scheduled_publishing_delay_seconds":  null,
    "schema_name":  "detailed_guide",
    "title":  "Fees applied to animal medicine authorisation applications",
    "updated_at":  "2025-01-03T13:07:58+00:00",
    "withdrawn_notice":  {
                             "explanation":  "\u003cdiv class=\"govspeak\"\u003e\u003cp\u003eWithdrawn as new fees applied under Veterinary Medicines Regulations 2013, as amended.\u003c/p\u003e\n\u003c/div\u003e",
                             "withdrawn_at":  "2024-05-16T16:40:51Z"
                         }
}
